Skip to main content
. 2023 Mar 9;17:1061485. doi: 10.3389/fnins.2023.1061485

FIGURE 4.

FIGURE 4

Stroke in T2DM-mice exacerbates NAFLD progression while CD133 + Exo treatment significantly reduces steatosis, fibrosis, NAS, and ALT activity. (A–C) Representative images of Oil red O (ORO), hematoxylin and eosin (H&E) staining and PicroSirius Red (PSR). T2DM-stroke mice exhibit significantly increased liver steatosis (D), increased ballooning degeneration of hepatocytes (E), increased fibrosis (F), increased serum ALT activity (G), and higher NAS (H) compared to T2DM-Sham mice. CD133 + Exo treatment of T2DM-stroke mice significantly decreased liver steatosis, hepatocellular ballooning, fibrosis, serum ALT activity, and NAS compared to T2DM-stroke mice at 28 days after stroke. NAS is the unweighted sum of scores for steatosis (0–3), lobular inflammation (0–3) and hepatocellular ballooning (0–2). Non-DM (WT, n = 6), non-DM-stroke (WT-Stroke, n = 15), T2DM (n = 8), T2DM-stroke (n = 12), and T2DM-stroke + Exo (n = 13).